Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Teva Pharmaceuticals acquired Allergan generics division for $40.5 billion, combining the world largest and third-largest generic drug manufacturers.
Israel Teva Pharmaceuticals completed a $40.5 billion acquisition of Allergan global generic pharmaceutical business, executing a strategic shift to combine…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Teva acquired Allergan's global generics business (formerly Actavis Generics) for approximately $40.5 billion in cash and stock, becoming the world's largest generics pharmaceutical company by revenue with over 1,000 generic molecules across all major markets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Allergan plc (Generics Business) (this deal) | 2015 | $40.5B | 23 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2015 deals · Teva Pharmaceutical Industries Ltd. deals · Cardiovascular deals